A direct assessment of the uterine microbiome in patients with endometrial cancer has revealed a potential predictive role for vaginal microbes.
As mortality rates continue to climb in endometrial cancer, there remains a pressing need for effective screening and diagnostics.
The use of CT-planned high-dose-rate intracavitary brachytherapy demonstrated excellent local control and survival for patients with stage I/II cervical carcinoma, according to the results of a recent study published in Gynecologic Oncology.
Patients with endometrial cancer who receive surgery in the first 2 weeks after diagnosis have worse survival outcomes, according to a study recently reported in the American Journal of Obstetrics and Gynecology.
An association was found between the use of nonsteroidal anti-inflammatory drugs and endometrial cancer risk.
Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.
Oncologists continue to face several challenges when it comes to the prevention and treatment of cervical cancer, according to Michael Birrer, MD, PhD.
Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.
Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.
Pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.